OnabotulinumtoxinA for chronic migraine: a critical appraisal
Rubesh Gooriah, Fayyaz Ahmed Department of Neurology, Hull Royal Infirmary, Kingston Upon Hull, UK Abstract: Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its b...
Kaydedildi:
Asıl Yazarlar: | , |
---|---|
Materyal Türü: | Kitap |
Baskı/Yayın Bilgisi: |
Dove Medical Press,
2015-06-01T00:00:00Z.
|
Konular: | |
Online Erişim: | Connect to this object online. |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
Yer Numarası: |
A1234.567 |
---|---|
Kopya Bilgisi 1 | Kütüphanede |